TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01341405
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, celecoxib 200 mg, once daily for 28 days
Study: NCT01500005
Drug: Baby D3 drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000-4000 iu per day
Study: NCT02615366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00818298
Drug: ziprazidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
Study: NCT00214682
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
Study: NCT01181830
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 8.1 mmol bid of placebo
Study: NCT03310593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention.
Study: NCT02156596
Drug: IV Serum Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of SS is given by IV root over 30 minutes
Study: NCT02156596
Drug: Nebulised Serum Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 nebulisations of 5ml SS each are given over 30 minutes
Study: NCT02194205
Drug: COMBIVENT HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02194205
Drug: Placebo HFA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02194205
Drug: COMBIVENT CFC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02194205
Drug: Placebo CFC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01103011
Drug: ND0611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous delivery of ND0611
Study: NCT00452543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 capsules PO TID, for 12 weeks
Study: NCT01103011
Drug: ND0611
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of ND0611 delivered continuously
Study: NCT00996216
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
Study: NCT01852110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK-7622 capsule
Study: NCT01852110
Drug: AChEI
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally
Study: NCT00709514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02413008
Drug: estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% estriol vaginal gel
Study: NCT02413008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo vaginal gel
Study: NCT01385423
Drug: Preparative Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
Study: NCT00299455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
Study: NCT02026479
Drug: Ginaton
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/pill, 3times/day,oral
Study: NCT01590199
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01590199
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01437722
Drug: 1% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal gel
Study: NCT01437722
Drug: 3% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal gel
Study: NCT01437722
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal gel
Study: NCT02085317
Drug: acetylcholine Iontophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
Study: NCT01516515
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01516515
Drug: SR-T100 with 2.3% of SM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3% of SM in Solanum undatum plant extract
Study: NCT00391404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01062360
Drug: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study: NCT01062360
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study: NCT01062360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
Study: NCT00760578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral
Study: NCT02828072
Drug: usual drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02989194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of placebo
Study: NCT00107445
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02583698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04687878
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day, intranasally, every day for 12 weeks
Study: NCT04525664
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg per os twice daily for 14 consecutive days.
Study: NCT01070745
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
Study: NCT01070745
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
Study: NCT00903695
Drug: Memory XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
Study: NCT00903695
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT00351117
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose in gelatin capsule that same as St. John's wort
Study: NCT01082120
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets orally, twice daily for 10 days
Study: NCT03355027
Drug: Rosuvastatin 20Mg Tablet
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT03355027
Drug: Rosuvastatin 40Mg Tablet
Normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT01011634
Drug: Intravenous moderate sedation versus oral medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
Study: NCT01102400
Drug: MEDI-575
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
Study: NCT03045627
Drug: AraC
Normalized name: Carac
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
Study: NCT03045627
Drug: Peg-G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-G-CSF 6mg subcutaneously on days 0.
Study: NCT02929927
Drug: 2.5%NaClO
Approvals — FDA: no, EMA: no, PMDA: no
Description: use 2.5% NaClO as irrigants
Study: NCT00166114
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
Study: NCT01601626
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg orally once daily from entry to Week 24.
Study: NCT01572454
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
Study: NCT00892749
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04629170
Drug: SYNB8802
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration
Study: NCT03549897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Product
Study: NCT03549897
Drug: 90 mcg Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
Study: NCT01380873
Drug: Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01380873
Drug: Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01380873
Drug: Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03251768
Drug: rHSA-GCSF 2.4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Serum Albumin GCSF 2.4mg at day 3 and day 7
Study: NCT03549897
Drug: 180 mcg Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
Study: NCT03549897
Drug: 90 mcg Test Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
Study: NCT03355027
Drug: Simvastatin 80mg
Normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT01654367
Drug: Zoledronic Acid and Aromatase Inhibitors
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
Study: NCT01674270
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00777478
Drug: capiri-sutent
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
Study: NCT03905603
Drug: rhCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhCG (Ovidrel) 250 mcg will be given once during the study.
Study: NCT01613326
Drug: Placebo to NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237 50 μg once a day delivered via SDDPI
Study: NCT00361738
Drug: AVE2268
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02245828
Drug: QCC374
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple ascending doses of QCC374
Study: NCT02245828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02200081
Drug: MGN1703
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00857558
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administration once a day for 12 weeks
Study: NCT01526135
Drug: mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)
Study: NCT04162210
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide and Dexamethasone will be administered.
Study: NCT01323205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (s) orally twice daily with a meal for 4 weeks.
Study: NCT01323205
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
Study: NCT03803267
Drug: Fentanyl NCS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (1µg/Kg)
Study: NCT03803267
Drug: Anesthesia Maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalational isoflurane in oxygen/air mixture
Study: NCT00993707
Drug: CTX-100 (formerly ETX-100) (hyaluronic acid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort.
Study: NCT03803267
Drug: Muscle Relaxation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
Study: NCT04370431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control for Part A of the study
Study: NCT04370431
Drug: TTYP01, 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTYP01 oral tablets (30 mg edaravone per tablet)
Study: NCT04370431
Drug: TTYP01, 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTYP01 oral tablets (30 mg edaravone per tablet)
Study: NCT04370431
Drug: Radicut® (ampoule), 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
Study: NCT04370431
Drug: Radicut® (bag) , 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
Study: NCT04370431
Drug: TTYP01, up to 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
Study: NCT02004717
Drug: DS-8895a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00420095
Drug: Human insulin 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
Study: NCT00393705
Drug: Insulin Biphasic Aspart 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
Study: NCT02718378
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03959150
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluorouracil
Study: NCT03163615
Drug: Tibet Rhodiola Capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, po, from admission up to 84 days
Study: NCT03163615
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules, po, from admission up to 84 days
Study: NCT00134251
Drug: SLV308
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01835548
Drug: NT0102
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
Study: NCT01835548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching ODT placebo was given once daily.
Study: NCT01898845
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01896531
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
Study: NCT01896531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT03316222
Drug: GNS561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses to be administered 3 times a week.
Study: NCT02190318
Drug: spirolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01380808
Drug: capecitabine and pseudomonas aeruginosa combination
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
Study: NCT01294293
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04403971
Drug: Listerine Oral Liquid Product
Normalized name: Listerine Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
Study: NCT03247686
Drug: RSLV-132
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNase Fc fusion protein
Study: NCT03247686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01016340
Drug: MCS
Normalized name: MCS Leg Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCS-5 Softgel 5 mg
Study: NCT01520987
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
Study: NCT01520987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily
Study: NCT03017352
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00855920
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
Study: NCT01466374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
Study: NCT01466374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
Study: NCT03797001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, daily for 24 weeks
Study: NCT00001723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Study: NCT04658277
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention arm will take Clarithromycin 250mg daily.